Delivery or therapeutic capable agents
First Claim
Patent Images
1. A luminal prosthesis comprising:
- a scaffold which is implantable within a body lumen; and
means on the scaffold for releasing a substance, wherein the substance is released over a predetermined time pattern comprising an initial phase wherein a substance delivery rate is below a threshold level and a subsequent phase wherein the substance delivery rate is above a threshold level.
1 Assignment
0 Petitions
Accused Products
Abstract
A device and a method using the same, for reducing restenosis and hyperplasia after intravascular intervention. In particular, the present invention provides luminal prostheses which allow for controlled release of at least one therapeutic capable agent with increased efficacy to selected locations within a patient'"'"'s vasculature to reduce restenosis. An intraluminal prosthesis may comprise an expandable structure and a source adjacent the expandable structure for releasing the therapeutic capable agent into the body lumen to reduce smooth muscle cell proliferation.
-
Citations
271 Claims
-
1. A luminal prosthesis comprising:
-
a scaffold which is implantable within a body lumen; and
means on the scaffold for releasing a substance, wherein the substance is released over a predetermined time pattern comprising an initial phase wherein a substance delivery rate is below a threshold level and a subsequent phase wherein the substance delivery rate is above a threshold level. - View Dependent Claims (2, 3, 4, 5, 6, 7)
-
- 8. An improved method for delivering a pharmacological agent to an artery, said method being of the type where a prosthesis is implanted within the artery and the prosthesis releases the pharmacological agent, wherein the improvement comprises implanting a prosthesis that is programmed to begin substantial release of the pharmacological agent beginning after growth of at least one layer of cells over a part of the prosthesis.
-
10. A method for luminal substance delivery, said method comprising:
-
providing a luminal prosthesis incorporating or coupled to the substance, wherein the prosthesis contains a matrix which undergoes degradation in a vascular environment; and
implanting the prosthesis in a body lumen so that at least a portion of the matrix degrades over a predetermined time period and substantial substance release begins after the matrix substantially begins to degrade. - View Dependent Claims (11, 12, 13, 14, 15, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 57, 58, 59, 60, 61, 62)
-
-
16. A method for treatment of a patient, comprising:
-
providing a vascular prosthesis comprising a structure and at least one source of at least one therapeutic capable agent associated with the structure;
implanting the vascular prosthesis within the patient'"'"'s vasculature including a susceptible tissue site;
releasing at least one therapeutic capable agent.
-
-
56. A method for delivering a therapeutic capable a gent to a susceptible tissue site within a corporeal body, comprising:
-
positioning a source of the therapeutic capable agent within a vascular lumen;
releasing the therapeutic capable agent to the susceptible tissue site.
-
-
63. A method for delivering a therapeutic capable agent to a susceptible tissue site, comprising:
-
positioning a device comprising a structure and at lease one source of at least one therapeutic capable agent associated with the structure, at a targeted intracorporeal site within a corporeal body;
releasing the therapeutic capable agent at the targeted intracorporeal site. - View Dependent Claims (64, 65, 66, 67, 68, 69, 70, 71, 72, 73)
-
-
74. A device for intracorporeal use, comprising:
-
a structure; and
at lease one source of at least one therapeutic capable agent associated with the structure. - View Dependent Claims (75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 145, 146, 147, 148, 149, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 239, 240, 242, 243, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271)
-
-
144. The device of 113 or 115 wherein the rate-controlling element has thickness ranging from about 10 nm to about 100 um.
-
150. A device for intracorporeal use, comprising:
-
an expandable member having at least one of luminal and tissue facing surfaces; and
at lease one source of at least one therapeutic capable agent disposed adjacent at least one of the luminal or tissue facing surfaces. - View Dependent Claims (257)
-
-
238. A device for intracorporeal use, comprising:
-
an expandable structure;
a source of therapeutic capable agent disposed adjacent the expandable structure, and including a plurality of rate-controlling element layers at least one of which comprises parylast or parylene, each layer having a thickness in a range from about 50 nm to 10 microns.
-
-
241. A device for intracorporeal use, comprising:
-
an expandable structure having luminal and tissue facing surfaces;
a source of therapeutic capable agent disposed adjacent at least one of the luminal or tissue facing surfaces; and
a rate-controlling element disposed adjacent the source.
-
-
244. An intracorporeal device for delivering at least one therapeutic capable agents to a targeted area in a corporeal body, comprising:
-
an expandable;
a source of therapeutic capable agent disposed adjacent the expandable structure and configured to delay the release of the therapeutic capable.
-
Specification